Buchumschlag

Beyond GLP ‐1

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Zachary Bloomgarden
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Journal of Diabetes
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

An Update on GLP‐1 Receptor Agonists
von: Zachary Bloomgarden
Veröffentlicht: (2025)

Updates in Type 1 Diabetes ( T1D ): What Recent Findings Might Mean for Treatment and Prevention Strategies
von: Zachary Bloomgarden
Veröffentlicht: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
von: Zachary Bloomgarden
Veröffentlicht: (2024)

Cardiovascular Disease, Cancer and Dementia in Diabetes: 20‐Year Trends Will Necessitate New Treatment Priorities
von: Zachary T. Bloomgarden
Veröffentlicht: (2026)

What will we see in diabetes in the next 10 years?
von: Zachary T. Bloomgarden
Veröffentlicht: (2024)

Recent Articles—Skeletal Muscle and Other Topics in Diabetes
von: Zachary Bloomgarden
Veröffentlicht: (2025)

The 2023 WCIRDC: Obesity
von: Zachary T. Bloomgarden
Veröffentlicht: (2024)

What is in a name and other peeves
von: Zachary Bloomgarden
Veröffentlicht: (2024)

Diabetic kidney disease—Recent updates
von: Zachary Bloomgarden
Veröffentlicht: (2024)

Imelda Lee—A memorial note
von: Zachary Bloomgarden
Veröffentlicht: (2024)

Diabetic Kidney Disease Update
von: Christian Mende, et al.
Veröffentlicht: (2025)

Deciphering the connection: Diabetes, pericyte dysfunction, and their impact on cardiovascular health
von: Robert Chilton, et al.
Veröffentlicht: (2024)

Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
von: Fei Lu
Veröffentlicht: (2026)

Reply: Time‐Related Biases in Observational Studies of GLP ‐1 Agonists and Cancer Risk
von: Zhiyuan Cheng, et al.
Veröffentlicht: (2026)

The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review
von: Jimmy Wen, et al.
Veröffentlicht: (2025)

Adverse Liver and Renal Outcomes After Initiating SGLT‐2i and GLP‐1RA Therapy Among Patients With Diabetes and MASLD
von: Arunkumar Krishnan, et al.
Veröffentlicht: (2025)

Cardiovascular and kidney benefits of GLP ‐1 receptor agonists across large randomized placebo‐controlled trials
von: Satoshi Yoshiji, et al.
Veröffentlicht: (2025)

Identifying Provider Prescribing Practices for GLP‐1RAs and SGLT‐2is in Patients With Type 2 Diabetes to Address Pharmacoinequity
von: Parnnate Wongsirisakul, et al.
Veröffentlicht: (2026)

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials
von: Yue Yin, et al.
Veröffentlicht: (2025)

Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
von: Sanbao Chai, et al.
Veröffentlicht: (2024)

Commentary on “Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes ( post hoc analysis of RECAP study)”
von: Yu Zhang, et al.
Veröffentlicht: (2025)

Usefulness of Once‐Weekly GLP‐1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study
von: Tomohiko Kimura, et al.
Veröffentlicht: (2024)

Beyond diabetes and obesity: GLP ‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation
von: Renata Spezani, et al.
Veröffentlicht: (2025)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
von: Mikhail Khachaturov, et al.
Veröffentlicht: (2026)

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes
von: Lasin Ozbek, et al.
Veröffentlicht: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
von: Roberta Scairati, et al.
Veröffentlicht: (2026)

Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
von: Rayanne Santos de Paulo, et al.
Veröffentlicht: (2026)

Incretin Hormone Levels (GLP‐1 and GIP) in Children and Adolescents With Type 1 Diabetes: A Systematic Review
von: Trine Witzner Hessel Lawaetz, et al.
Veröffentlicht: (2025)

Residual Gastric Content in Hospitalised GLP ‐ 1RA Users: Considerations for Interpretation
von: Jiajia Xia
Veröffentlicht: (2026)

GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
von: Tommaso Bucci, et al.
Veröffentlicht: (2025)

Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety
von: Hans Johnson, et al.
Veröffentlicht: (2025)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
von: Richard J. MacIsaac, et al.
Veröffentlicht: (2024)

Characterization of Novel WFS1 Variants in Three Diabetes Pedigrees
von: ChangQing Liu, et al.
Veröffentlicht: (2025)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
von: Inyoung Hwang, et al.
Veröffentlicht: (2026)

Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
von: Brianna Sa, et al.
Veröffentlicht: (2025)

Effects of GLP‐1 Receptor Agonists on Paediatric Population in a Real World Setting
von: A. G. Barajas, et al.
Veröffentlicht: (2025)

Future directions for quality of life research with second‐generation GLP ‐ 1RAs for obesity
von: Robert Hsu, et al.
Veröffentlicht: (2024)

β‐Cell gene expression stress signatures in types 1 and 2 diabetes
von: Xiaoyan Yi, et al.
Veröffentlicht: (2024)

Insights Into Macrophage Polarization and M1 / M2 Balance in Diabetic Foot Ulcers
von: Jing Zhang, et al.
Veröffentlicht: (2026)

November 11–12, 2025, T1DX‐QI Learning Session, Journal of Diabetes
Veröffentlicht: (2026)